Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Dermatology > AAD 2023 > New Developments in Dermatology > Nemolizumab decreases lesions and itch in prurigo nodularis

Nemolizumab decreases lesions and itch in prurigo nodularis

Presented by
Prof. Shawn Kwatra , Johns Hopkins University School of Medicine, MD, USA
Medical Writer
Susanne Kammerer
Conference
AAD 2023
Trial
Phase 3, OLYMPIA 2
Doi
https://doi.org/10.55788/78e0533d
    The phase 3 OLYMPIA 2 trial observed an improvement in skin lesions, itch, and other symptoms of prurigo nodularis (PN) on active treatment with nemolizumab. In addition, therapy with the IL-31 inhibitor led to a significant decrease in sleep disturbances.

    Patients diagnosed with the neuroimmune disease PN, suffer from intense pruritus and pruritic papulonodules that negatively influences sleep and quality of life [1]. IL-31 is believed to play a major role in the pathogenesis of PN and is seen as a driver of the associated itch-scratch cycle [2].

    The OLYMPIA 2 trial (NCT04501679) was designed to assess the IL-31 Receptor α antagonist nemolizumab for its potential in treating PN [3]. After a 2:1 randomisation, the 274 adult participants with PN were treated with either subcutaneous nemolizumab at a dosage of 30 mg (bodyweight <90 kg) or 60 mg (bodyweight ≥90 kg) every 4 weeks or placebo. The co-primary endpoints were defined as an at least 4-point improvement in the Peak Pruritus Numerical Rating Scale (PP-NRS) at week 16 and the percentage of participants with Investigator’s Global Assessment (IGA) success in terms of a score of 0/1 plus a ≥2-grade reduction at the same time point.

    The participants had a mean age of 52.7 years, just over 60% were women, and 43% experienced severe itch on the average weekly PP-NRS. Prof. Shawn Kwatra (Johns Hopkins University School of Medicine, MD, USA) emphasised that 37.2% had a nodule count of >100.

    Compared with baseline, 56.3% of participants on nemolizumab and 20.9% on placebo reached a ≥4-point PP-NRS amelioration (P<0.0001). Of note, significant differences were present as early as week 4. Furthermore, a greater proportion of IGA success was noted in the nemolizumab arm than in the placebo arm: 37.7% versus 11.0% (P<0.0001). The agent also led to a significant decrease in sleep disturbance of ≥4-point on the PP-NRS: 51.9% for nemolizumab versus 20.9% for placebo (P<0.0001).

    Any kind of treatment-emergent events happened in 61.2% on nemolizumab and 52.7% on placebo, with a proportion of any serious events in 2.2% and 5.5%, respectively. Among the most common events (≥5%), headache and atopic dermatitis occurred more often in the nemolizumab group (6.6% vs 4.4% and 5.5% vs 0%). Worsening of prurigo (neurodermatits) however, happened more often in the placebo group (3.8% vs 11.0%).

    All in all, the monotherapy with nemolizumab involved significant benefits in itch, lesions, and sleep impairments, while showing a consistent safety profile.

    1. Williams KA, et al. Expert Rev Clin Pharmacol. 2021;14:67–77.
    2. Tsoi LC, et al. J Allergy Clin Immunol. 2022;149:1329–39.
    3. Kwatra S. Nemolizumab monotherapy improves itch, skin lesions, and sleep disturbance in patients with prurigo nodularis: Results from a phase 3 trial (OLYMPIA 2). S025, AAD 2023 Annual Meeting, 17-21 March, New Orleans, USA.




    Posted on